65619-29-6

Usage

Uses

Used in Pharmaceutical Industry:
4-CYANO-4-(3-CHLOROPHENYL)CYCLOHEXANONE is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 4-CYANO-4-(3-CHLOROPHENYL)CYCLOHEXANONE serves as an intermediate in the production of agrochemicals, contributing to the development of effective pesticides and other agricultural chemicals.
Used in Organic Synthesis:
4-CYANO-4-(3-CHLOROPHENYL)CYCLOHEXANONE is utilized as a building block in organic synthesis, enabling the preparation of a wide range of organic compounds for various applications, including the creation of new materials and the development of novel chemical processes.
Used in Antimalarial Research:
4-CYANO-4-(3-CHLOROPHENYL)CYCLOHEXANONE has been studied for its potential antimalarial properties, making it a candidate for further research and development as a possible treatment for malaria.
Used in Anti-inflammatory Applications:
4-CYANO-4-(3-CHLOROPHENYL)CYCLOHEXANONE has also been investigated for its anti-inflammatory properties, suggesting its potential use in the development of medications to treat inflammation-related conditions.

Upstream product

• 65619-21-8 4-(3-chloro-phenyl)-4-cyanoheptanedioic acid dimethyl ester. 
• 1529-41-5 3-chloro-benzeneacetonitrile 
• 65619-25-2 5-(3-chlorophenyl)-5-cyano-2-oxo-cyclohexanecarboxylic acid methyl ester 

Downstream Products

• 37408-65-4 2-[4-(3-Chloro-phenyl)-4-cyano-cyclohex-1-enyl]-propionic acid ethyl ester 
• 1037235-24-7 [8-(3-chlorophenyl)-1,4-dioxa-spiro[4.5]dec-8-ylmethyl]carbamic acid tert-butyl ester 
• 1037197-18-4 C₂₃H₃₄Cl₂N₂O₃ 
• 1037236-27-3 C₁₈H₂₅ClN₄O₂ 
• 1037235-85-0 methanesulphonic acid [trans-4-(tert-butoxycarbonylaminomethyl)-4-(3-chlorophenyl)cyclohexyl] ester 
• 1552306-25-8 C₂₉H₃₆ClF₃N₄O₂ 
• 1552306-29-2 C₂₉H₃₄ClF₃N₄O₃ 
• 1037235-28-1 ({cis-1-(3-chlorophenyl)-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]cyclohexyl}methyl)-carbamic acid tert-butyl ester 
• 1037235-38-3 [1-(cis-3-chlorophenyl)-4-(8-oxo-3-trifluoromethyl-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)cyclohexylmethyl]carbamic acid tert-butyl ester 
• 1037235-26-9 [1-(3-chlorophenyl)-4-oxo-cyclohexylmethyl]-carbamic acid tert-butyl ester 
• 887978-99-6 C-[8-(3-chlorophenyl)-1.4-dioxa-spiro[4.5]dec-8-yl]methylamine 
• 1037360-81-8 C₂₄H₂₈ClF₃N₄ 
• 1037361-22-0 C₂₄H₂₆ClF₃N₄O 

Relevant academic research and scientific papers

PHARMACEUTICAL COMPOUNDS

This invention relates to compounds that are agonists of the muscarinic M1 receptor or M1 and M4 receptors and which are useful in the treatment of muscarinic M1 or M1/M4 receptor mediated

DI(HETERO)ARYLCYCLOHEXANE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM

The present invention relates to di(hetero)arylcyclohexane derivatives of the formula (I), in which Ar1, Ar2, R1 and R2 have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmaceutical active compounds which inhibit ATP-sensitive potassium channels in the heart muscle and are suitable, for example, for the treatment of disorders of the cardiovascular system such as arrhythmias or a decreased contractility of the heart, such as can occur, for example, in coronary heart disease, cardiac insufficiency or cardiomyopathies. In particular, they are suitable for the prevention of sudden cardiac death. The invention furthermore relates to processes and intermediates for the preparation of the compounds of the formula (I), their use and pharmaceutical compositions comprising them.

1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS

Compounds of the formula (I) are provided: wherein V, W, X, Y, Z, R3, R4, R5, R6, R7 and m are as defined in the specification; and pharmaceutically acceptable salts and prodrugs thereof. The compound

4-Amino-4-arylcyclohexanones and Their Derivatives, a Novel Class of Analgesics. 1. Modification of the Aryl Ring

Investigation of central nervous system activity of phenylcyclohexylamines was continued by preparation of "reversed" analogues.Following the unexpected finding of analgesic activity with 1-(dimethylamino)-1-phenylcyclohexylamine, the SAR of the series was investigated.Synthesis starts by double Michael reaction of acrylate on arylacetonitriles.Following cyclization, decarboxylation, ketalization, and saponification, the geminally substituted acid is rearranged to the isocyanate by means of (C6H5O)2PON3.Isocyanates were then converted to the title compounds.Analgesic activity is very sensitive to the nature and position of the substituent on the aromatic ring.The most potent compounds in this series (p-CH3, p-Br) showed 50percent the potency of morphine.Deletion of the ring oxygen abolishes activity.